Details

Autor(en) / Beteiligte

• Kim, Seong-Geun
• Oh, Sung Yong
• Kwon, Hyuk-Chan
• Lee, Suee
• Kim, Jung Hwan
• Kim, Sung-Hyun
• Kim, Hyo-Jin

Titel

A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer

Ist Teil von

• Japanese journal of clinical oncology, 2007-10, Vol.37 (10), p.744-749

Ort / Verlag

England: Oxford University Press

Erscheinungsjahr

2007

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• AbstractObjective This phase II study was designed to assess the safety and efficacy of a modified FOLFIRI regimen (irinotecan with bi-weekly, low dose leucovorin (ldLV) and bolus and continuous infusion with 5-fluorouracil (5-FU)) as a salvage therapy for patients with advanced or metastatic gastric cancer. Methods Patients were treated with irinotecan 150 mg/m2 on day 1 and received ldLV 20 mg/m2 followed by 5-FU 400 mg/m2 (bolus) and 5-FU 600 mg/m2 (22 h continuous infusion) on days 1 and 2 every 14 days. Results A total of 36 patients were assigned to treatment. The median patient age was 55 years (range 31–70), and 55.6% (20/36) of the patients had performance status (ECOG) of 0 or 1.The median follow-up duration was 15.5 (range 2.6–36.4) months. Of the 30 patients evaluated for their tumor response, three achieved a partial response, with an overall response rate of 10.0% (95% CI 0.0–21.0%). Eleven patients (36.7%) showed stable disease. The median time to progression was 3.3 (95% CI 2.0–4.6) months, and the median overall survival time was 10.9 (95% CI 6.1–15.7) months. The median number of cycles of modified FOLFIRI treatment was 3 (range 1–9 cycles). Grade III or IV neutropenia was observed in 23 cycles (17.6%), and febrile neutropenia occurred in three cycles (2.3%). Grade III nausea/vomiting was found in one patient (2.8%). There was one episode of UGI bleeding, but there were no treatment-related deaths. Conclusion The modified FOLFIRI regimen described here appears a safe and feasible salvage therapy in advanced gastric cancer patients.